Product Description
Hanmi Company Limited was developing hcp-1303, an oral PDE5 Inhibitor,ADRA1A Antagonist for erectile dysfunction and prostatic Hyperplasia
Mechanisms of Action: PDE5 Inhibitor, ADRA1A Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hanmi
Company Location: Western America
Company CEO: Bonita I. Lee
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Prostatic Hyperplasia
Phase 1: Erectile Dysfunction|Prostatic Hyperplasia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02715401 |
HM-TASU-103 | P1 |
Completed |
Erectile Dysfunction|Prostatic Hyperplasia |
2015-11-01 |
2019-03-20 |
Treatments |
|
NCT02712411 |
HM-TASU-102 | P1 |
Completed |
Prostatic Hyperplasia|Erectile Dysfunction |
2015-08-01 |
2019-03-20 |
Treatments |
|
NCT02667938 |
HM-TASU-301 | P3 |
Completed |
Prostatic Hyperplasia |
2016-01-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|